Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa
Locations
Other Locations
Egypt
Faculty of Medicine, Menoufia University
RECRUITING
Tanta
Contact Information
Primary
Mostafa M Bahaa, PhD
mbahaa@horus.edu.eg
0201025538337
Time Frame
Start Date: 2023-01-06
Estimated Completion Date: 2025-11-20
Participants
Target number of participants: 60
Treatments
Experimental: Control Group
Control group ( Levo-dopa group, n =30 ) who will receive levodopa/carbidopa (50/250 mg) three times daily for 3 months
Active_comparator: Metformin group
Patients will receive levodopa/carbidopa (50/250 mg) three times daily plus metformin 500 mg two times daily for 3 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University
Collaborators: Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University